Adrenal Cortex Neoplasms Market

Market Overview:

The 7 major adrenal cortex neoplasms markets reached a value of USD 23.5 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 29.8 Million by 2035, exhibiting a growth rate (CAGR) of 2.20% during 2025-2035.

The adrenal cortex neoplasms market has been comprehensively analyzed in IMARC's new report titled "Adrenal Cortex Neoplasms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Adrenal cortex neoplasms are a group of rare tumors that arise from the outer layer of the adrenal gland. This gland is located on top of each kidney and plays a crucial role in producing various hormones that regulate metabolism, blood pressure, and stress response. Individuals suffering from the ailment may experience abdominal pain, unintentional weight loss, headaches, heavy sweating, excessive hair growth (in women), high blood pressure, hormonal imbalances, etc. Various other symptoms of the illness include a feeling of fullness, difficulty breathing, muscle weakness, trouble sleeping, decreased appetite, heart palpitations, fatigue, nervousness, etc. The diagnosis of adrenal cortex neoplasms usually involves a combination of the patient’s medical history, characteristic findings, and a physical examination. Several blood and urine workups may be performed to evaluate hormone levels and assess the functioning of the adrenal glands. These investigations can include dexamethasone suppression tests, 24-hour urine collection, hormone assays, etc. In certain cases, the healthcare provider will recommend a tissue biopsy to confirm the diagnosis and determine the nature of the tumor.

The increasing cases of genetic conditions, which cause rearrangements in genes that affect normal cellular functions and promote tumor formation, are primarily driving the adrenal cortex neoplasms market. In addition to this, the inflating utilization of hormone replacement therapy since it aims to replace or supplement the deficient hormones, such as cortisol and aldosterone, among patients is also creating a positive outlook for the market. Moreover, the widespread adoption of whole-exome sequencing techniques, which enable the simultaneous analysis of multiple genes or even the entire genome to identify novel mutations or fusion genes that might be causing the disease, is further bolstering the market growth. Apart from this, the rising usage of immune checkpoint inhibitors to help in activating the immune system as well as allowing it to recognize and attack cancerous cells more effectively is acting as another significant growth-inducing factor. Additionally, the emerging popularity of targeted therapies that are more precise in their mechanism of action, aiming at specific molecules or receptors involved in tumor growth, is expected to drive the adrenal cortex neoplasms market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the adrenal cortex neoplasms market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for adrenal cortex neoplasms and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adrenal cortex neoplasms market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adrenal cortex neoplasms market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adrenal cortex neoplasms market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current adrenal cortex neoplasms marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the adrenal cortex neoplasms market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the adrenal cortex neoplasms market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the adrenal cortex neoplasms market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of adrenal cortex neoplasms across the seven major markets?
• What is the number of prevalent cases (2019-2035) of adrenal cortex neoplasms by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of adrenal cortex neoplasms by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with adrenal cortex neoplasms across the seven major markets?
• What is the size of the adrenal cortex neoplasms patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of adrenal cortex neoplasms?
• What will be the growth rate of patients across the seven major markets?
   

Adrenal Cortex Neoplasms: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for adrenal cortex neoplasms drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adrenal cortex neoplasms market?
• What are the key regulatory events related to the adrenal cortex neoplasms market?
• What is the structure of clinical trial landscape by status related to the adrenal cortex neoplasms market?
• What is the structure of clinical trial landscape by phase related to the adrenal cortex neoplasms market?
• What is the structure of clinical trial landscape by route of administration related to the adrenal cortex neoplasms market?